Last reviewed · How we verify

NCT04292119

Lorlatinib Combinations in Lung Cancer

Status unknown Phase 1, PHASE2 Last updated 10 March 2021
What this trial tests

Phase 1, PHASE2 trial testing Lorlatinib in Lung Cancer in 96 participants. Status unknown.

Timeline
1 May 2020
Primary endpoint
1 December 2022
1 March 2023

Quick facts

Lead sponsorMassachusetts General Hospital
PhasePhase 1, PHASE2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment96
Start date1 May 2020
Primary completion1 December 2022
Estimated completion1 March 2023
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Lung Cancer or Anaplastic Lymphoma Kinase Gene Translocation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is evaluating Lorlatinib in combination with Crizotinib, Binimetinib, or TNO155 as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer. * This research study involves four study drugs. * Lorlatinib * Binimetinib * Crizotinib * TNO155

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. The current state of the art and future trends in RAS-targeted cancer therapies.
    Punekar SR, Velcheti V, Neel BG, Wong KK. · · 2022 · cited 382× · PMID 36028717 · DOI 10.1038/s41571-022-00671-9
  2. ALK-positive lung cancer: a moving target.
    Schneider JL, Lin JJ, Shaw AT. · · 2023 · cited 131× · PMID 36797503 · DOI 10.1038/s43018-023-00515-0
  3. Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers.
    Dillon M, Lopez A, Lin E, Sales D, et al · · 2021 · cited 99× · PMID 34680208 · DOI 10.3390/cancers13205059
  4. Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders.
    Stanford SM, Bottini N. · · 2023 · cited 80× · PMID 36693907 · DOI 10.1038/s41573-022-00618-w
  5. SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment.
    Sodir NM, Pathria G, Adamkewicz JI, Kelley EH, et al · · 2023 · cited 69× · PMID 37682219 · DOI 10.1158/2159-8290.cd-23-0383
  6. Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.
    D'Angelo A, Sobhani N, Chapman R, Bagby S, et al · · 2020 · cited 66× · PMID 33172113 · DOI 10.3390/cancers12113293
  7. The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
    Gristina V, La Mantia M, Iacono F, Galvano A, et al · · 2020 · cited 56× · PMID 33352844 · DOI 10.3390/ph13120474
  8. Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review.
    Desai A, Lovly CM. · · 2023 · cited 32× · PMID 37057106 · DOI 10.21037/tlcr-22-708

Verify or expand the search:

Other trials of Lorlatinib

Trials testing the same drug.

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

Other Massachusetts General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04292119.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing